Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Aytu BioPharma, Inc. (AYTU) had Revenue of $15.16M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$15.16M
Net Income	$-10.58M
Cost of Goods Sold	$5.54M
Gross Profit	$9.62M
Operating Expenses	$17.14M
Operating Income	$-1.97M
Non-Operating Income/Expense	$-8.61M
Pre-Tax Income	$-10.58M
Normalized Pre-Tax Income	$-10.58M
Income after Taxes	$-10.58M
Income from Continuous Operations	$-10.58M
Consolidated Net Income/Loss	$-10.58M
Normalized Income after Taxes	$-10.58M
EBIT	$-1.97M
EBITDA	$-1.06M
Weighted-Average Shares Outstanding (Basic)	10.04M
Weighted-Average Shares Outstanding (Diluted)	10.04M
Earnings per Share (EPS) (Basic)	$-1.05
Earnings per Share (EPS) (Diluted)	$-1.05
Balance Sheet Financials
Current Assets	$76.24M
Property, Plant, and Equipment	$0.48M
Long-Term Assets	$45.76M
Total Assets	$122.00M
Current Liabilities	$65.56M
Long-Term Debt	$10.00M
Long-Term Liabilities	$42.24M
Total Liabilities	$107.80M
Common Equity	$14.20M
Tangible Shareholders Equity	$-29.38M
Shareholders Equity	$14.20M
Common Shares Outstanding	10.73M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$3.06M
Cash Flow from Investing Activities	$-0.02M
Cash Flow from Financial Activities	$-3.97M
Beginning Cash	$30.95M
End Cash	$30.02M
Increase/Decrease in Cash	$-0.93M
Stock-Based Compensation	$0.40M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.16
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.41
Debt to Equity Ratio	1.47
Gross Margin	63.46%
Operating Margin	-12.99%
EBIT Margin	-12.99%
EBITDA Margin	--
Pre-Tax Profit Margin	-69.79%
Profit Margin	-69.79%
Free Cash Flow	$3.04M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.12
Inventory Turnover	0.64
Receiveable Turnover	0.49
Days Sales in Receivables	183.52
Return on Equity	-74.53%
Return on Tangible Equity	36.03%
Return on Assets	-8.68%
Return on Investments	-43.74%
Book Value Per Share	$1.32
Free Cash Flow per Share	$0.30
Operating Cash Flow per Share	$0.30

Data from Zacks Investment Research, Inc.